PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media295246ArticlesСтатьиResearch ArticlePOSSIBILITIES OF METHORMINE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS: TEST OF TIMEВОЗМОЖНОСТИ МЕТФОРМИНА В ЛЕЧЕНИИ САХАРНОГО ДИАБЕТА 2 ТИПА: ИСПЫТАНИЕ ВРЕМЕНЕМBiryukovaE. VБирюковаЕ. В

MD, Prof., MSMSU

д.м.н., проф.

lena@obsudim.ruSolovyevaI. VСоловьеваИ. ВPlatonovaN. MПлатоноваН. МMoscow State Medical Stomatological University n.a. A.I. EvdokimovМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваScientific Medical Research Center of EndocrinologyНаучный медицинский исследовательский центр эндокринологии15042018254NO4 (2018)№4 (2018)596527022023Copyright ©; 2018, Bionika MediaCopyright ©; 2018, ООО «Бионика Медиа»2018Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/295246

Type 2 diabetes mellitus (DM2) is an actual modern medical and social problem. The review article discusses the pathogenesis of the disease. The important role of insulin resistance as a key link in the development of DM2 is emphasized. Details of the mechanism of action of metformin, its glycemic and extra-glycemic effects, the place of the drug in modern diabetes therapy are considered.

Сахарный диабет 2 типа (СД2) - актуальная медико-социальная проблема современности. В обзорной статье обсуждаются вопросы патогенеза заболевания. Подчеркивается важная роль инсулинорезистентности как ключевого звена развития СД2. Детально рассматриваются механизм действия метформина, его гликемические и внегликемические эффекты, место препарата в современной терапии СД.

type 2diabetes mellitusinsulin resistancehypoglycemic therapymetforminсахарный диабет 2 типаинсулинорезистентностьсахароснижающая терапияметформинIDF http://www.diabetesatlas.org/Дедов И.И., Шестакова М.В. Сахарный диабет. 2007;3:55-7.Kooy A., de Jager J., Lehert P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern Med. 2009;169:616-25.Hemmingsen B., Lund S., Wetterslev J., Vaag A. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur. J. Endocrinol. 2009;161:1-9.Meier M., Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc. Health Risk Manag. 2009;5:859-71.Bailey C.J., Turner R.C. Metformin. N. Engl. J. Med. 1996;334:574-79.Rotella C.M., Monami M., Mannucci E. Metformin beyond diabetes: new life for an old drug. Curr. Diabet. Rev. 2006;2:307-15.Mann-Pehalver J.J., Martln-Timon I., Sevillano-Collantes C., Del Cahizo-Gomez F.J. Update on the treatment of type 2 diabetes mellitus. World J. Diabet. 2016;7(17):354-95. Doi: 10.4239/ wjd.v7.i17.354.Kinaan M., Ding H., Triggle C.R. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Med. Princ. Pract. 2015;24:401-15. Doi: 10.1159/000381643.Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin. An Update. Ann. Intern. Med. 2002;137:25-33.Godarzi M.O., Brier-Ash M. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabet. Obes. Metab. 2005;5:654-65.UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-65.Rojas L.B.A., Gomes M.B. Metformin: an old but still the best treatment for type 2 diabetes Diabet. Metabolic. Syndrome. 2013;5:6. Doi. org/10.1186/1758-5996-5-6.Coutinho M., Gerstein H., Wang Y., Yusuf S. The relationship between glucose and incident cardiovascular events, a metaregression analysis of published data from 20 studies of 95783 individuals followed for 12,4 years. Diabet. Care. 1999;22:233-40.Coughlan K.A., Valentine R.J., Ruderman N.B., et al. AMPK activation: a therapeutic target for type 2 diabetes? Diabet. Metab. Syndr. Obes. 2014;7:241-53.Foretz M., He'brard S., Leclerc J., Zarrinpashneh E., Soty M., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010;120:2355-69.Markowicz-Piasecka M., Huttune M.K., Lukasz M., et al. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. Curr. Pharm. Des. 2017;23:1-19.Pryor R., Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem. J. 2015;471(3):307-22.Shinmura K., Negoro T., Shimizu S., et al. Metformin Modulates GLP-1- and GIP-Mediated Intracellular Signaling under Normoglycemic Conditions. Open J. Endocr. Metab. Dis. 2013;3:263-70.McCreight L.J., Bailey C.J., Pearson E.R. Metformin and the gastrointestinal tract. Diabet. 2016;59(3):426-35.Lien F., Berthier A., Bouchaert E., et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J. Clin. Invest. 2014;124:1037-51.Schwartz S.S., Epstein S., Corkey B.E., et al. The time is right for a new classification system for diabetes: rationale and implications of the ß-cell-centric classification schema. Diabet. Care. 2016;39:179-86.Мкртумян А.М., Бирюкова Е.В. Болезни сердца и сосудов. 2007;2:31-5.Berkowitz S.A., Krumme A.A., Avorn J. Initial choice of oral glucose-lowering medication for diabetes mellitus a patient-centered comparative effectiveness study. JAMA. Intern. Med. 2014;174(12):1955-62. Doi:10.1001/ jamainternmed.2014.5294.Malin S.K., Kashyap S.R Effects of metformin on weight loss: potential mechanisms. Current Opinion in Endocrinology, Diabet. Obes. 2014;21(5):323-29.Kim H.-J., Jin B.Y., Oh M.-J., Shin K.-H., ChoiS.-H., Kim D.-H. The effect of metformin on neuronal activity in the appetite-regulating brain regions of mice fed a high-fat diet during an anorectic period. Physiol. Behavior. 2016;154:184-19. Doi.org/10.1016/j.physbeh.2015.11.028.Malin S.K., Sangeeta R.K. Effects of metformin on weight loss: potential mechanisms. Current Opinion in Endocrinology, Diabet. Obes. 2014;21(5):323-9. Doi: 10.1097/ MED.0000000000000095.Chau-Van C., Gamba M., Salvi R., et al. Metformin Inhibits Adenosine 5'-Monophosphate-Activated Kinase Activation and Prevents Increases in Neuropeptide Y Expression in Cultured Hypothalamic Neurons. Endocrinol. 2007;148(2):507-11.Li Y., Xu S., Mihaylova M.M., et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell. Metab. 2011;13:376-88.Mamputu J.C., Wiernsperger N.F., Renier G.A. Antiatherogenic properties of metformin: the experimental evidence. Diabet. Metab. 2003;29:6S71-76.Ouslimani N., Mahrouf M., Peynet J., et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism. 2007;56(3):308-13.Chakraborty A., Chowdhury S., Bhattacharyya M. Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabet. Res. Clin. Pr. 2011;93:56-62.Johnson J.A., Majumdar S.R., Simpson S.H: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabet. Care. 2002;25:2244-48.Kao J., Tobis J., Mc Clelland R.L. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am. J. Cardiol. 2004;93:1347-50. Doi:10.1016/j.amjcard.2004.02.028.Holden S.E., Jenkins-Jones S., Currie C.J. Association between Insulin Monotherapy versus Insulin plus Metformin and the Risk of All-Cause Mortality and Other Serious Outcomes: A Retrospective Cohort Study. PLoS One. 2016;6;11(5):e0153594. Doi: 10.1371/ journal.pone.0153594.Lee H., Ko G. Effect of metformin on metabolic improvement and gut microbiota. Appl. Environ Microbiol. 2014;80:5935-43.Кожевников А.А., Раскина К.В., Мартынова Е.Ю. Тяхт А. Участие кишечной микробиоты в процессах метаболизма, старения и перспективы применения имеющихся данных в реальной клинической практике. РМЖ. «Медицинское обозрение» 2017;2:98-105.Decensi A., et al. Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev. Res. (Phila). 2010;3(11):1451-61.Coyle C., Cafferty F.H., Vale C., et al. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann. Oncol. 2016;27(12):2184-95.Kasznicki J., Sliwinska A., Drzewoski J. Metformin in cancer prevention and therapy. Ann. Transl. Med. 2014;2(6):57. Doi: 10.3978/j.issn.2305-5839.2014.06.01.Topcu S., Tok D., Caliskan M. Metformin therapy improves coronary microvascular function in patient with polycystic ovary syndrom and insulin resistence. Clin. Endocrinol. (Oxf). 2006;65(1):75-80.